SCHEMBL5228056

SCHEMBL5228056

CN1CC2CCN(C(=O)OC(C)(C)C)CC2(Cc2ccccc2)C1=O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 2/20 0.46
JAK2 O60674 1/20 0.46
JAK1 P23458 1/20 0.46
STS P08842 1/20 0.46
KEAP1 Q14145 1/20 0.44
NFE2L2 Q16236 1/20 0.44
KDM4E B2RXH2 1/20 0.43
PKM P14618 1/20 0.43
PDE4A P27815 1/20 0.42
PDE4B Q07343 1/20 0.42
PDE4C Q08493 1/20 0.42
PDE4D Q08499 1/20 0.42
GAA P10253 1/20 0.42
THRB P10828 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
LMNA P02545 1/20 0.42
KLK7 P49862 1/20 0.41
USP30 Q70CQ3 2/20 0.41
RORC P51449 3/20 0.41
TACR1 P25103 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5230646 0.82 STS (0.45) GPR119JAK2JAK1STSKEAP1
SCHEMBL5229014 0.82 STS (0.48) GPR119JAK2JAK1STSKEAP1
SCHEMBL5226618 0.77 GHSR (0.49) KLK7
SCHEMBL22722159 0.76 GPR119 (0.47) GPR119JAK2JAK1STSKEAP1
SCHEMBL30360504 0.76 GPR119 (0.47) GPR119JAK2JAK1STSKEAP1
SCHEMBL5227875 0.75 CHRM3 (0.46) GAA
SCHEMBL5226505 0.75 GHSR (0.63)
SCHEMBL5229351 0.75 GHSR (0.63)
SCHEMBL5227028 0.75 GHSR (0.63)
SCHEMBL7494453 0.74 GPR119 (0.54) GPR119JAK2JAK1STSKEAP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1001970-B1 DIPEPTIDE DERIVATIVES AS GROWTH HORMONE SECRETAGOGUES PFIZER (US) 2007-03-07 EP disclosed
US-6953791-B2 Dipeptide derivatives PFIZER, INC. (US) 2005-10-11 US disclosed
US-6951850-B2 Dipeptide derivatives PFIZER, INC. (US) 2005-10-04 US disclosed
US-6924280-B2 Dipeptide derivatives PFIZER INC. (US) 2005-08-02 US disclosed
US-RE38524-E1 Dipeptide derivatives as growth hormone secretagogues PFIZER INC. 2004-06-01 US disclosed
US-20040009984-A1 Increasing levels of endogenous growth hormone, especially treating osterporosis, aging frailty or congestive heart failure CARPINO PHILIP ALBERT (US) 2004-01-15 US disclosed
US-20040006063-A1 Dipeptide derivatives CARPINO PHILIP ALBERT (US) 2004-01-08 US disclosed
US-20030216399-A1 Dipeptide derivatives CARPINO PHILIP ALBERT (US) 2003-11-20 US disclosed
US-6525047-B2 Which are growth hormone secretogogues and increase the level of endogenous growth hormone; treating osteoporosis, congestive heart failure, frailty associated with aging, obesity; accelerating bone fracture repair PFIZER INC. 2003-02-25 US disclosed
US-20020183243-A1 Polyglutamic acid-camptothecin conjugates and methods of preparation CELL THERAPEUTICS, INC. 2002-12-05 US disclosed
US-6432945-B1 Dipeptide derivatives PFIZER INC. 2002-08-13 US disclosed
US-6433171-B1 FOR OSTEOPOROSIS AND/OR FRAILTY, CONGESTIVE HEART FAILURE, FRAILTY ASSOCIATED WITH AGING, OBESITY; ACCELERATING BONE FRACTURE REPAIR, ATTENUATING PROTEIN CATABOLIC RESPONSE AFTER A MAJOR OPERATION, REDUCING CACHEXIA AND PROTEIN LOSS PFIZER INC. 2002-08-13 US disclosed
US-6429313-B2 Dipeptide derivatives PFIZER INC. 2002-08-06 US disclosed
US-20020042415-A1 Dipeptide derivatives CARPINO PHILIP ALBERT (US) 2002-04-11 US disclosed
US-20010041703-A1 Dipeptide derivatives CARPINO PHILIP ALBERT (US) 2001-11-15 US disclosed
US-6251902-B1 Dipeptide derivatives as growth hormone secretagogues PFIZER INC. 2001-06-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040009984-A1 Increasing levels of endogenous growth hormone, especially treating osterporosis, aging frailty or congestive heart failure GHSR, GHRHR, GIPR GPR119 59/4885JAK2 2129/4885JAK1 3489/4885
US-20020042415-A1 Dipeptide derivatives GIPR, GHRHR, GHSR GPR119 53/4885JAK2 2148/4885JAK1 3343/4885
US-20010041703-A1 Dipeptide derivatives GIPR, GHRHR, GHSR GPR119 55/4885JAK2 2130/4885JAK1 3262/4885
US-20020183243-A1 Polyglutamic acid-camptothecin conjugates and methods of preparation QPCT, DCLRE1A, FOLH1 GPR119 4011/4885JAK2 1081/4885JAK1 2796/4885
US-20040006063-A1 Dipeptide derivatives GIPR, GHRHR, GHSR GPR119 40/4885JAK2 1570/4885JAK1 3055/4885
US-20030216399-A1 Dipeptide derivatives GIPR, GHRHR, GHSR GPR119 53/4885JAK2 2148/4885JAK1 3343/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.